Method of Treating Expressive Language Deficit in Autistic Humans
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,980,603 | Method of Treating Expressive Language Deficit in Autistic Humans In force · High confidence UsedRemaining | AMS Therapeutics | In force | High confidence | ||
| US 12,599,581 | Method of Treating Expressive Language Deficit in Autistic Humans In force · Medium confidence | AMS Therapeutics, LLC | In force | Medium confidence | ||
| Application 18/620,897 | Method of Treating Expressive Language Deficit in Autistic Humans Abandoned Abandoned Mar 12, 2026 | AMS Therapeutics | Abandoned | Abandoned Mar 12, 2026 |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by AMS AG.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.